Capricor Therapeutics Provides BLA Regulatory Insights

Summary

On June 24, 2025, Capricor Therapeutics provided regulatory insights concerning their Biologics License Application (BLA) for Deramiocel, aimed at treating Duchenne muscular dystrophy (DMD)-related cardiac disease. Capricor Therapeutics is listed on NASDAQ under the ticker CAPR and focuses on innovative cell and exosome therapies for rare diseases.Unusual Whales

Impact Analysis

This event is classified at the company level as it specifically concerns Capricor Therapeutics and its regulatory progress related to Deramiocel. The provision of regulatory insights is a critical step toward potential approval and commercialization, which could positively impact the company’s stock price due to expected revenue growth from new therapies. Analysts have maintained a ‘Buy’ rating with an average target price of $39.50, indicating positive market expectations.Trading View The announcement might trigger immediate investor interest and drive up stock prices, particularly given the recent positive analyst ratings and significant institutional investment interest seen through option activities.Benzinga+ 2 However, ongoing investigations by Pomerantz LLP may introduce risks and should be monitored.Benzinga